Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cholecalciferol × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 19 Other hematologic neoplasm 15 Gastrointestinal 14 Genitourinary 13 Lymphoid 12 Dermatologic 6 Myeloid 5 CNS 5 Gynecologic 4 Classical hematology 3 Other 2 Tumor-Agnostic 1 Thoracic 1 Other neoplasm 1 Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 53 lutetium Lu 177 dotatate 41 Magnetic Resonance Spectroscopy 27 Cisplatin 25 pembrolizumab 24 Temozolomide 22 Octreotide 20 Nivolumab 20 lanreotide 19 gallium Ga 68 dotatate 19 Specimen Handling 17 cabozantinib 16 Etoposide 16 Sunitinib 14 Capecitabine 14 pasireotide 13 lenvatinib 13 dabrafenib 13 Paclitaxel 13 Carboplatin 13 trametinib 12 surufatinib 11 Doxorubicin 11 Bevacizumab 11 3-Iodobenzylguanidine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Ipilimumab 10 Injections 10 Thyrotropin Alfa 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02063334 2016-07-29

VitDbol

University of Eastern Finland

Phase 1 Completed

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡